AMPH Stock Up 46% after 5-Day Win Streak
Amphastar Pharmaceuticals (AMPH) stock hit day 5 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 46% return. The company has gained about $661 Mil in value over the last 5 days, with its current market capitalization at about $1.4 Bil. The stock remains 17.9% below its value at the end of 2024. This compares with year-to-date returns of 9.9% for the S&P 500.
AMPH provides generic and proprietary injectable, inhalation, and intranasal products, including over-the-counter asthma relief and hyaluronidase injections, in the U.S., China, and France. After this rally, is AMPH still a buy – or is it time to lock in gains? Deep dive with Buy or Sell AMPH.
Comparing AMPH Stock Returns With The S&P 500
The following table summarizes the return for AMPH stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | AMPH | S&P 500 |
|---|---|---|
| 1D | 0.4% | 0.3% |
| 5D (Current Streak) | 46.4% | 1.9% |
| 1M (21D) | 43.9% | 3.6% |
| 3M (63D) | 27.6% | 9.9% |
| YTD 2025 | -17.9% | 9.9% |
| 2024 | -40.0% | 23.3% |
| 2023 | 120.7% | 24.2% |
| 2022 | 20.3% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. However, big gains can follow sharp reversals – but how has AMPH behaved after prior drops? See AMPH Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 114 S&P constituents with 3 days or more of consecutive gains and 11 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 49 | 2 |
| 4D | 33 | 5 |
| 5D | 20 | 3 |
| 6D | 5 | 0 |
| 7D or more | 7 | 1 |
| Total >=3 D | 114 | 11 |
Key Financials for Amphastar Pharmaceuticals (AMPH)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $644.4 Mil | $732.0 Mil |
| Operating Income | $197.0 Mil | $205.4 Mil |
| Net Income | $137.5 Mil | $159.5 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $170.5 Mil | $174.4 Mil |
| Operating Income | $37.3 Mil | $42.2 Mil |
| Net Income | $25.3 Mil | $31.0 Mil |
While AMPH stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.